Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.

Suzanne Trudel, MD, Susan Lee, Christopher J. Kirk, PhD, Nashat Gabrail, MD, Sagar Lonial, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Vishal Kukreti, MD, FRCPC, A. Keith Stewart, MD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Francis Buadi, MD, Jeffrey A Zonder, MD, Mark K Bennett, PhD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 1845.

https://doi.org/10.1182/blood.V114.22.1845.1845

Published: 2009

Journal Articles

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Tony Muchamuel, Shirin Kapur, PhD, Christopher J Kirk, Ph.D, Jing Jiang, M.D., Susan Lee, Mark K Bennett, PhD, Evan Lewis, Jinfu Yang, Mouhannad Jumaa, Eileen Ring, Pasit Phiasivongsa, Han-Jie Zhou, PhD, Zhengping Wang

Blood (2009) 114 (22): 4910.

https://doi.org/10.1182/blood.V114.22.4910.4910

Published: 2009

Journal Articles

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

Ravi Vij, MD, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., A. Keith Stewart, MD, Sundar Jagannath, MD, Sagar Lonial, MD, Suzanne Trudel, MD, Andrzej J Jakubowiak, MD, PhD, Andrew Belch, MD, Melissa Alsina, MD, Nizar J Bahlis, MD, Mai H. Le, MD, Scott Cruickshank, BA, MS, Mark K Bennett, PhD, Susan Molineaux, PhD, Michael Kauffman, MD, PhD, David Siegel, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 430.

https://doi.org/10.1182/blood.V114.22.430.430

Published: 2009

Journal Articles

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

Luhua Wang, MD, David Siegel, Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Andrzej J Jakubowiak, MD, PhD, Melissa Alsina, MD, Vishal Kukreti, MD, FRCPC, Nizar J Bahlis, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Michael Sebag, MD, PhD, Nashat Gabrail, MD, Mai H. Le, MD, Mark K Bennett, PhD, Lori Kunkel, MD, Michael Kauffman, MD, PhD, Robert Z Orlowski, M.D., Ph.D., Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 302.

https://doi.org/10.1182/blood.V114.22.302.302

Published: 2009

Journal Articles

Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib.

Erika Suzuki, Susan Demo, PhD, Shirin Arastu-Kapur, PhD, Christopher J Kirk, Ph.D, Mark K Bennett, PhD

Blood (2009) 114 (22): 2852.

https://doi.org/10.1182/blood.V114.22.2852.2852

Published: 2009

Journal Articles

Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms.

Shirin Arastu-Kapur, PhD, Andrew J. Ball, PhD, Janet L. Anderl, Mark K Bennett, PhD, Christopher J Kirk, Ph.D

Blood (2009) 114 (22): 2859.

https://doi.org/10.1182/blood.V114.22.2859.2859

Published: 2009

Journal Articles

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

David Siegel, Luhua Wang, MD, Robert Z Orlowski, M.D., Ph.D., Jonathan L. Kaufman, MD, A. Keith Stewart, MD, Vishal Kukreti, MD, FRCPC, Melissa Alsina, MD, Andrzej J Jakubowiak, MD, PhD, Sundar Jagannath, MD, Kevin T. McDonagh, MD, Andrew Belch, MD, Nizar J Bahlis, MD, Chaim Shustik, MD, Mai H. Le, MD, Lori Kunkel, MD, Mark K Bennett, PhD, Michael Kauffman, MD, PhD, Ravi Vij, MD, The Multiple Myeloma Research Consortium (MMRC)

Blood (2009) 114 (22): 303.

https://doi.org/10.1182/blood.V114.22.303.303

Published: 2009

Journal Articles

Pharmacokinetics, Metabolism, Distribution and Excretion of Carfilzomib in Rats.

Jinfu Yang, Rachel Fang, Zhengping Wang, Jing Jiang, Tony Muchamuel, Susan Lee, Christopher J Kirk, Francisco Zhao, Mark K Bennett, Christopher J. Molineaux

Blood (2009) 114 (22): 2754.

https://doi.org/10.1182/blood.V114.22.2754.2754

Published: 2009

Journal Articles

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

Francesco Parlati, Susan J. Lee, Monette Aujay, Erika Suzuki, Konstantin Levitsky, James B. Lorens, David R. Micklem, Paulina Ruurs, Catherine Sylvain, Yan Lu, Kevin D. Shenk, Mark K. Bennett

Blood (2009) 114 (16): 3439–3447.

https://doi.org/10.1182/blood-2009-05-223677

Published: 2009

Includes: Supplemental data

Journal Articles

The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration

Christopher J Kirk, Jing Jiang, Tony Muchamuel, Maya Dajee, Deborah Swinarski, Monette Aujay, Mark K Bennett, PhD, Jinfu Yang, Evan Lewis, Guy Laidig, Christopher J. Molineaux, PhD

Blood (2008) 112 (11): 2765.

https://doi.org/10.1182/blood.V112.11.2765.2765

Published: 2008

Journal Articles

Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib

Shirin Arastu-Kapur, Kevin Shenk, Francesco Parlati, Mark K Bennett

Blood (2008) 112 (11): 2657.

https://doi.org/10.1182/blood.V112.11.2657.2657

Published: 2008

Journal Articles

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Tony Muchamuel, Monette Aujay, Mark K Bennett, PhD, Maya Dajee, Susan Demo, PhD, Christopher J Kirk, Ph.D, Ying Fang, Jing Jiang, M.D., Evan Lewis, Yan Lu, Guy Laidig, Francesco Parlati, PhD, Jamie Shields, Congcong m Sun, Jinfu Yang, Han-Jie Zhou, PhD

Blood (2008) 112 (11): 3671.

https://doi.org/10.1182/blood.V112.11.3671.3671

Published: 2008

Journal Articles

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Fijs W. B. van Leeuwen, Asher A. Chanan-Khan, Robert Z. Orlowski

Blood (2007) 110 (9): 3281–3290.

https://doi.org/10.1182/blood-2007-01-065888

Published: 2007

Includes: Supplemental data

Journal Articles

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Deborah J. Kuhn, PhD, Qing Chen, PhD, Peter M. Voorhees, MD, John S. Strader, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Fred W. van Leeuwen, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3461.

https://doi.org/10.1182/blood.V108.11.3461.3461

Published: 2006

Journal Articles

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.

Susan D. Demo, PhD, Monette A. Aujay, BS, Eileen Goldstein, BS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Yan Lu, PhD, Kevin D. Shenk, BS, Congcong M. Sun, MS, Catherine Sylvain, PhD, Tina M. Woo, BS, Hanjie Zhou, PhD, Mark K. Bennett, PhD

Blood (2006) 108 (11): 4398.

https://doi.org/10.1182/blood.V108.11.4398.4398

Published: 2006

Journal Articles

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Francesco Parlati, PhD, Monette A. Aujay, B.S., Susan D. Demo, Ph.D., Eileen D. Goldstein, B.S., Jing Jiang, B.S., Christopher J. Kirk, Ph.D., Guy J. Laidig, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Kevin D. Shenk, M.S., Catherine Sylvain, Ph.D., Congcong M. Sun, M.S., Tina M. Woo, B.S., Han-Jie Zhou, Ph.D., Mark K. Bennett, Ph.D.

Blood (2006) 108 (11): 4392.

https://doi.org/10.1182/blood.V108.11.4392.4392

Published: 2006

Journal Articles

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

Christopher J. Kirk, PhD, Monette A. Aujay, B.S., Mark Ho, B.S., Jing Jiang, B.S., Guy J. Laidig, Ph.D., Evan R. Lewis, Ph.D., Yan Lu, M.S., Tony Muchamuel, M.S., Tina M. Woo, B.S., Congcong M. Sun, M.S., Catherine Sylvain, Ph.D., Jinfu Yang, Ph.D., Han-jie Zhou, Ph.D., Mark K. Bennett, Ph.D.

Blood (2006) 108 (11): 3581.

https://doi.org/10.1182/blood.V108.11.3581.3581

Published: 2006

Journal Articles

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells.

Douglas Ivancsits, Rama Nimmanapali, PhD, Megan Sun, Kevin Shenk, Susan D. Demo, PhD, Mark K. Bennett, PhD, William S. Dalton, MD, PhD, Melissa Alsina, MD

Blood (2005) 106 (11): 1575.

https://doi.org/10.1182/blood.V106.11.1575.1575

Published: 2005

Journal Articles

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Deborah J. Kuhn, PhD, Peter M. Voorhees, MD, John S. Strader, PA, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Robert Z. Orlowski, MD, PhD

Blood (2005) 106 (11): 1576.

https://doi.org/10.1182/blood.V106.11.1576.1576

Published: 2005

Journal Articles

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171.

Susan D. Demo, PhD, Tonia J. Buchholz, MS, Guy J. Laidig, PhD, Francesco Parlati, PhD, Kevin D. Shenk, BS, Mark S. Smyth, PhD, Carol M. Sullivan, BA, Congcong M. Sun, MS, Marcy K. Vallone, BS, Tina Woo, BS, Mark K. Bennett, PhD

Blood (2005) 106 (11): 1588.

https://doi.org/10.1182/blood.V106.11.1588.1588

Published: 2005

NARROW

Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients.

Dose Intensive Administration of PR-047, a Novel Orally Bioavailable Inhibitor of the 20S Proteasome, Is Well Tolerated in Experimental Animals.

Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.

Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).

Bortezomib-Resistant Cell Lines Have Increased Proteasome Levels but Remain Sensitive to Carfilzomib.

Neurodegeneration Induced by Bortezomib Exposure in Vitro Occurs Via Proteasome Independent Mechanisms.

PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.

Pharmacokinetics, Metabolism, Distribution and Excretion of Carfilzomib in Rats.

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration

Non-Proteasomal Targets of Proteasome Inhibitors Bortezomib and Carfilzomib

Preclinical Pharmacology and in Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Identification of Peptide Epoxy-Ketone Proteasome Inhibitors with Differential Active Site Selectivity.

Immunoproteasome-Selective Keto-Epoxide Inhibitors: Potential Therapeutic Agents for the Treatment of Hematological Disorders.

Pharmacologic Evaluation of Orally Bioavailable Inhibitors of the 20S Proteasome.

The Proteasome Inhibitor PR-171 Inhibits Cell Growth, Induces Apoptosis, and Overcomes De Novo and Acquired Drug Resistance in Human Multiple Myeloma Cells.

Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.

Biochemical and Cellular Characterization of the Novel Proteasome Inhibitor PR-171.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only